(Q423308)

cabergoline (English)

3 October 2016

chemical formula

C₂₆H₃₇N₅O₂

1 reference

cabergoline (English)

19 November 2016

canonical SMILES

CCNC(=O)N(CCCN(C)C)C(=O)C1CC2C(CC3=CNC4=CC=CC2=C34)N(C1)CC=C

1 reference

cabergoline (English)

19 November 2016

isomeric SMILES

CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(C1)CC=C

1 reference

cabergoline (English)

https://www.whocc.no/atc_ddd_index/?code=N04BC06

19 November 2016

defined daily dose

3 milligram

route of administration

oral administration

1 reference

reference URL

0.5 milligram

route of administration

oral administration

1 reference

reference URL

https://www.whocc.no/atc_ddd_index/?code=G02CB03

World Health Organisation international non-proprietary name

cabergoline (English)

1 reference

cabergoline (English)

medical condition treated

3 October 2016

1 reference

13 December 2016

1 reference

benign neoplasm of pituitary gland

13 December 2016

1 reference

Drug Indications Extracted from FAERS

prolactin producing pituitary tumor

2 October 2018

1 reference

Drug Indications Extracted from FAERS

2 October 2018

prolactinoma

1 reference

Drug Indications Extracted from FAERS

significant drug interaction

2 October 2018

levomepromazine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

zuclopenthixol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(Z)-flupentixol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-sulpiride

1 reference

A reference set of clinically relevant adverse drug-drug interactions

droperidol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

fluphenazine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

haloperidol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

chlorpromazine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

physically interacts with

5-hydroxytryptamine receptor 1A

1 reference

5-hydroxytryptamine receptor 1B

17 August 2016

1 reference

5-hydroxytryptamine receptor 1D

17 August 2016

1 reference

5-hydroxytryptamine receptor 2A

17 August 2016

1 reference

5-hydroxytryptamine receptor 2B

17 August 2016

1 reference

5-hydroxytryptamine receptor 2C

17 August 2016

1 reference

17 August 2016

Adrenoceptor alpha 1A

1 reference

10 November 2016

Adrenoceptor alpha 2A

1 reference

10 November 2016

Adrenoceptor alpha 2B

1 reference

10 November 2016

Adrenoceptor alpha 2C

1 reference

10 November 2016

1 reference

17 August 2016

1 reference

17 August 2016

1 reference

17 August 2016

1 reference

17 August 2016

1 reference

imported from Wikimedia project

17 August 2016

pregnancy category

US pregnancy category B

1 reference

2 references

5 March 2018

Medical Subject Headings

15 March 2018

1 reference

Medical Subject Headings

15 March 2018

1 reference

Medical Subject Headings

15 March 2018

Cabergoline

0 references

Identifiers

InChI

InChI=1S/C26H37N5O2/c1-5-11-30-17-19(25(32)31(26(33)27-6-2)13-8-12-29(3)4)14-21-20-9-7-10-22-24(20)18(16-28-22)15-23(21)30/h5,7,9-10,16,19,21,23,28H,1,6,8,11-15,17H2,2-4H3,(H,27,33)/t19-,21-,23-/m1/s1

1 reference

cabergoline (English)

19 November 2016

2 references

cabergoline (English)

19 November 2016

ChEBI release 2020-09-01

CAS Registry Number

81409-90-7

2 references

Global Substance Registration System

UNII

LL60K9J05T

cabergoline (English)

19 November 2016

https://commonchemistry.cas.org/detail?cas_rn=81409-90-7

10 April 2021

1 reference

Cabergoline (English)

19 November 2016

2 references

cabergoline (English)

19 November 2016

Reaxys registry number

6020775

1 reference

cabergoline (English)

3 October 2016

ChEBI ID

3286

mapping relation type

2 references

CABERGOLINE (English)

19 November 2016

International Chemical Identifier

InChI

InChI=1S/C26H37N5O2/c1-5-11-30-17-19(25(32)31(26(33)27-6-2)13-8-12-29(3)4)14-21-20-9-7-10-22-24(20)18(16-28-22)15-23(21)30/h5,7,9-10,16,19,21,23,28H,1,6,8,11-15,17H2,2-4H3,(H,27,33)/t19-,21-,23-/m1/s1

1 reference

CABERGOLINE (English)

19 November 2016

2 references

inferred from InChIKey

Mapping file of InChIStrings, InChIKeys and DTXSIDs for the EPA CompTox Dashboard

1 reference

2 references

DSSTOX compound identifier

0 references

1 reference

ECHA Substance Infocard database

ECHA Substance Infocard ID

100.155.380

27 December 2018

ECHA Substance Infocard ID

1-[3-(dimethylamino)propyl]-3-ethyl-1-[(2R,4R,7R)-6-(prop-2-en-1-yl)-6,11-diazatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-1(16),9,12,14-tetraene-4-carbonyl]urea (English)

quotation

CAS no.: 81409-90-7 (English)

100.155.380

1 reference

ECHA Substance Infocard database

ECHA Substance Infocard ID

100.155.380

20 December 2018

1-[3-(dimethylamino)propyl]-3-ethyl-1-[(2R,4R,7R)-6-(prop-2-en-1-yl)-6,11-diazatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-1(16),9,12,14-tetraene-4-carbonyl]urea (English)

quotation

CAS no.: 81409-90-7 (English)

1 reference